Study
| Phase 3, randomized, double-blind, placebo-controlled trial (ECHELON-3) |
| Relapsed or refractory DLBCL after ≥2 lines of therapy, ineligible for or relapsed after SCT or CAR T-cell therapy |
| Brentuximab vedotin + lenalidomide + rituximab vs. placebo + lenalidomide + rituximab |
Efficacy
| ORR: 64% vs. 42% (BV + Len + R vs. placebo + Len + R) |
| CR: 40% vs. 19% |
| mOS: 13.8 mos vs. 8.5 mos (HR: 0.63 [0.45-0.89]) |
| mPFS: 4.2 mos vs. 2.6 mos (HR: 0.53 [0.38-0.73]) |
| mDoR: 8.3 mos vs. 3.0 mos |
Safety
| Grade ≥3 AEs: Neutropenia (43% vs. 28%), thrombocytopenia (25% vs. 19%), anemia (22% vs. 21%) |
| Febrile neutropenia: 9% in both arms |
| Peripheral neuropathy (any grade): 31% vs. 24%, grade 3: 6% vs. 2% |
| Serious AEs: 60% vs. 50% |
| Treatment-related deaths: 12% vs. 8% |
J Clin Oncol 2025;43:1061-72
Bartlett NL,Hahn U,Kim WS Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
http://doi.org/10.1200/JCO-24-02242
Reviewed by Ulas D. Bayraktar, MD on Apr 7, 2025
